Waszak and colleagues used rare variant burden analysis to estimate that germline mutations are responsible for 6% of medulloblastoma diagnoses and identified SUFU, PTCH1, APC, BRCA2, PALB2 and TP53 as consensus medulloblastoma risk genes [106]. This evidence concerns the gene PALB2 and medulloblastoma.